MACROGENICS INC (MGNX) Form 10-Q — Aug 14, 2026

$MGNXForm 10-QFiled Aug 14, 2026, 4:19 PM ET0001125345-26-000056Original filing

MacroGenics reported Q2 2026 total revenue of $32.8 million, up 375% year over year, driven by a one-time $24.5 million TZIELD regulatory milestone from Sanofi and a $6.0 million increase in ZYNYZ royalty revenue. The company swung to quarterly net income of $19.5 million, or $0.31 per share, powered by an $86.1 million gain on the sale of its CDMO operations. MacroGenics completed the sale of its contract development and manufacturing operations to Bora Pharmaceuticals on June 30, 2026, receiving $119.6 million net of adjustments in July 2026 against a $122.5 million headline price.

Key figures

Eps: $0.31 basic and diluted net income per share in Q2 2026; net loss from continuing operations of $(1.10) per share
Revenue: $32.8 million total revenue in Q2 2026 ($39.6 million for the six months ended June 30, 2026)
Net Income: $19.5 million net income in Q2 2026 (including $89.2 million income from discontinued operations); net loss from continuing operations of $69.6 million
Revenue Yoy: +375% YoY in Q2 2026 (vs. $6.9 million); +184% YoY for H1 2026
Cash Position: $113.9 million cash and equivalents plus $59.4 million marketable securities at June 30, 2026 (~$173.3 million total)
Deal Value Usd: $122.5 million cash consideration for the CDMO sale to Bora ($119.6 million net received in July 2026, up to $5.0 million contingent)
Interest Rate: approximately 7.40% effective interest rate under the amended Sagard royalty monetization arrangement
Shares Outstanding: 63700187
Cash runway: through 2028 per management
H1 net loss: $17.3 million (vs. $77.3 million in H1 2025)
Sanofi milestone: $24.5 million TZIELD regulatory milestone recognized in Q2 2026, payable September 2026
Cdmo gain on sale: $86.1 million net gain (after $8.8 million transaction costs); $94.8 million before transaction costs
Ga expense q2 2026: $7.9 million (down from $9.3 million)
Rd expense q2 2026: $38.8 million (down 5% YoY)
Accumulated deficit: $1.26 billion
Stockholders equity: $42.9 million (down from $55.6 million at December 31, 2025)
Gilead option payment: $10.0 million due from Gilead for August 2026 First Research Program option exercise
Sagard amendment proceeds: $60.0 million additional cash received effective May 1, 2026
Loss on royalty extinguishment: $52.8 million non-cash loss in Q2 2026
Sagard aggregate purchase price: $130.0 million
New royalty liability fair value: $181.0 million; balance of $178.1 million at June 30, 2026

Price after filing

1 day: 0.0%7 days: -2.8%30 days: -5.2%

Close on the filing date to close N calendar days later (from $4.22). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.